Literature DB >> 1381350

Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors.

V V Sardana1, E A Emini, L Gotlib, D J Graham, D W Lineberger, W J Long, A J Schlabach, J A Wolfgang, J H Condra.   

Abstract

Several novel, structurally distinct classes of specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) nonnucleoside inhibitors have been described recently. These include the pyridinone derivatives L-697,639, L-697,661, and L-696,229 as well as BI-RG-587 and the tetrahydroimidazo[4,5,1-j,k]-benzodiazepin-2(1H)-one and -thione compounds. Previous studies have implicated involvement of the RT amino acid residues at positions 103, 181, and 188 in the activity of the compounds. Accordingly, HIV-1 RT mutants containing a series of amino acid substitutions at these positions were constructed. The relative resistance of purified mutant enzymes to each of the inhibitors was assessed. This analysis established the functional equivalence of the three inhibitor classes and provided evidence for the interaction of the 103 site with the 181/188 region. Amino acid substitutions at these positions were also found to influence RT sensitivity to inhibition by phosphonoformate, thereby suggesting a close association between this pyrophosphate analog's binding site in RT and the binding site of the nonnucleoside inhibitors. In addition, aromatic stacking of the amino acid side groups at residues 181 and 188 was suggested to be required for inhibitor activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381350

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 2.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.

Authors:  A Hizi; R Tal; M Shaharabany; M J Currens; M R Boyd; S H Hughes; J B McMahon
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

4.  A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.

Authors:  T J Dueweke; T Pushkarskaya; S M Poppe; S M Swaney; J Q Zhao; I S Chen; M Stevenson; W G Tarpley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

5.  U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.

Authors:  T J Dueweke; S M Poppe; D L Romero; S M Swaney; A G So; K M Downey; I W Althaus; F Reusser; M Busso; L Resnick
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

6.  A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors.

Authors:  M E Goldman; J A O'Brien; T L Ruffing; W A Schleif; V V Sardana; V W Byrnes; J H Condra; J M Hoffman; E A Emini
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

7.  Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  P L Boyer; M J Currens; J B McMahon; M R Boyd; S H Hughes
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.

Authors:  R A Olmsted; D E Slade; L A Kopta; S M Poppe; T J Poel; S W Newport; K B Rank; C Biles; R A Morge; T J Dueweke; Y Yagi; D L Romero; R C Thomas; S K Sharma; W G Tarpley
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors.

Authors:  V W Byrnes; V V Sardana; W A Schleif; J H Condra; J A Waterbury; J A Wolfgang; W J Long; C L Schneider; A J Schlabach; B S Wolanski
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

10.  Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication.

Authors:  J P Kleim; R Bender; U M Billhardt; C Meichsner; G Riess; M Rösner; I Winkler; A Paessens
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.